Related Experiment Videos
PAC1-R null isoform expression in human prostate cancer tissue
Caterina Mammi1, Giovanni V Frajese, Giuseppe Vespasiani
1Department of Internal Medicine, Unit of Endocrinology, Faculty of Medicine, University of Rome Tor Vergata, Rome, Italy.
The Prostate
|December 24, 2005
Summary
Pituitary adenylate cyclase-activating polypeptide (PACAP) receptor variant PAC(1)-R null is highly expressed in prostate cancer (PCa). This finding suggests its role in PCa development and progression.
Area of Science:
- Molecular Endocrinology
- Oncology
- Prostate Cancer Research
Background:
- Pituitary adenylate cyclase-activating polypeptide (PACAP) influences prostate cell proliferation.
- PACAP belongs to the VIP/GHRH neuropeptide family.
Purpose of the Study:
- To analyze the expression and localization of PACAP and its receptor variants (PAC(1)-R) in benign prostatic hyperplasia (BPH) and prostate cancer (PCa) tissues.
- To investigate the role of PAC(1)-R variants in prostate pathologies.
Main Methods:
- Reverse transcriptase (RT)-polymerase chain reaction (PCR)
- DNA sequencing
- Immunohistochemistry
Main Results:
- PACAP and PAC(1)-R were localized in prostate tissues.
- In healthy and BPH tissues, PAC(1)-R staining was observed in epithelial and stromal cells.
- In PCa tissues, PAC(1)-R staining was primarily in the apical portion of cells, with the PAC(1)-R null variant being the most relevant isoform expressed.
Conclusions:
- The PAC(1)-R null variant is the predominant isoform in human PCa.
- PAC(1)-R null expression is suggestively related to prostate cancer outcomes.